David J. Woodhouse - Dec 29, 2021 Form 4 Insider Report for NGM BIOPHARMACEUTICALS INC (NGM)

Role
Chief Executive Officer, Director
Signature
/s/ Valerie Pierce, Attorney-in-fact
Stock symbol
NGM
Transactions as of
Dec 29, 2021
Transactions value $
$137,989
Form type
4
Date filed
12/30/2021, 04:09 PM
Previous filing
Nov 19, 2021
Next filing
Mar 4, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NGM Common Stock Options Exercise $100K +13K $7.70 13K Dec 29, 2021 Direct
transaction NGM Common Stock Options Exercise $38K +4.67K +35.94% $8.14 17.7K Dec 29, 2021 Direct
holding NGM Common Stock 80K Dec 29, 2021 See footnote F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NGM Stock Option (Right to Buy) Options Exercise $0 -13K -12.99% $0.00 87K Dec 29, 2021 Common Stock 13K $7.70 Direct F2
transaction NGM Stock Option (Right to Buy) Options Exercise $0 -4.67K -7.47% $0.00 57.8K Dec 29, 2021 Common Stock 4.67K $8.14 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares held by The Woodhouse Family Trust 9/8/05.
F2 Fully vested.
F3 The shares subject to the stock option are early exercisable and vest over a four-year period commencing January 1, 2018, with 1/48th of the shares vesting on a monthly basis.